<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02116660</url>
  </required_header>
  <id_info>
    <org_study_id>0518-284</org_study_id>
    <secondary_id>2013-001637-40</secondary_id>
    <nct_id>NCT02116660</nct_id>
  </id_info>
  <brief_title>Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)</brief_title>
  <acronym>RANIA</acronym>
  <official_title>Switching From Regimens Consisting of a RTV-Boosted Protease Inhibitor Plus TDF/FTC to a Combination of Raltegravir Plus Nevirapine and Lamivudine in HIV Patients With Suppressed Viremia and Impaired Renal Function (RANIA Study) (Pilot Study) Protocol MK-0518-284-02</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate changes in renal function, efficacy, and safety when switching from a combination
      of tenofovir/emtricitabine (TDF/FTC) plus a protease inhibitor/ritonavir (PI/r) to a
      combination of raltegravir (MK-0518) plus nevirapine plus lamivudine in human
      immunodeficiency virus (HIV)-1 participants with suppressed viremia and impaired renal
      function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 3, 2014</start_date>
  <completion_date type="Actual">July 10, 2017</completion_date>
  <primary_completion_date type="Actual">July 10, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>Baseline and Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Suppressed Viremia (&lt;50 copies/mL HIV-1 Ribonucleic Acid [RNA]) at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Suppressed Viremia (&lt;50 copies/mL HIV-1 RNA) at Week 96</measure>
    <time_frame>Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Decline in Renal Function at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Raltegravir plus Nevirapine plus Lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raltegravir 400 mg oral twice daily, plus nevirapine 200 mg oral once daily for 14 days followed by nevirapine 200 mg oral twice daily, plus lamivudine 150 mg oral twice daily for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir/emtricitabine 300/200 mg oral once daily plus 1) lopinavir/ritonavir 400/100 mg oral twice daily or 800/200 mg oral once daily, or 2) atazanavir/ritonavir 300/100 mg oral once daily, or 3) darunavir/ritonavir 800/100 mg oral once daily or 600/100 mg oral twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir (MK-0518)</intervention_name>
    <description>Raltegravir (MK-0518) 400 mg tablets</description>
    <arm_group_label>Raltegravir plus Nevirapine plus Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <description>Nevirapine (NVP) 200 mg tablets</description>
    <arm_group_label>Raltegravir plus Nevirapine plus Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Lamivudine (3TC) 150 mg tablets</description>
    <arm_group_label>Raltegravir plus Nevirapine plus Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <description>Tenofovir disoproxil fumarate (TDF) 300 mg tablets</description>
    <arm_group_label>Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine</intervention_name>
    <description>Emtricitabine (FTC) 200 mg tablets</description>
    <arm_group_label>Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir</intervention_name>
    <description>Lopinavir (LPV) 200 mg tablets</description>
    <arm_group_label>Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Ritonavir (r) 100 mg tablets</description>
    <arm_group_label>Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>Atazanavir (ATV) 300 mg tablets</description>
    <arm_group_label>Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>Darunavir (DAR) 400 mg tablets</description>
    <arm_group_label>Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, or non-pregnant, non-breastfeeding female

          -  No previous history of virological failure

          -  No previous exposure to non-nucleoside reverse transcriptase inhibitors or integrase
             inhibitors

          -  No previous history of intolerance to lamivudine

          -  At least 2 documented plasma HIV-1 RNA &lt;50 copies/mL and no HIV-1 &gt;50 copies/mL in the
             12 months before screening

          -  Receiving the same protease inhibitor/ritonavir plus tenofovir/emtricitabine
             combination for at least the 6 months before screening

          -  Has no major International Antiviral Society (IAS)-USA mutations on genotype testing
             performed before starting antiretroviral treatment

          -  Sexually-active participants and their partners of child-bearing potential agree to
             use a medically acceptable method of contraception from 2 weeks before Day 1 and for
             at least 6 months after the last dose of study drug (postmenopausal women are not
             required to use contraception; sexually-active male participants with a female partner
             of child-bearing potential must provide written informed consent to information
             regarding any pregnancy)

        Exclusion Criteria:

          -  Positive for hepatitis B surface antigen (HBsAg+) or anticipated need for hepatitis C
             virus treatment

          -  Liver cirrhosis

          -  Has a history of diabetes mellitus, defined as initiation of antidiabetic treatment or
             verification of diabetes in a case report form

          -  Has any cancer, excluding stable Kaposi Sarcoma

          -  Allergy or sensitivity to the investigational product or excipients

          -  Female participant who is nursing

          -  Female participant who is pregnant or intends to become pregnant

          -  Has an active Acquired Immunodeficiency Syndrome (AIDS)-defining event except stable
             Kaposi Sarcoma or HIV Wasting Syndrome

          -  Received any investigational drug within 30 days before screening

          -  Participated in any other clinical trial within 30 days before signing informed
             consent for the current trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2014</study_first_submitted>
  <study_first_submitted_qc>April 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2014</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Viremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

